Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries has reported results for the fourth quarter and year ended March 31, 2018.

The company has reported a rise of 83.30% in its net profit at Rs 176.26 crore for the quarter ended March 31, 2018 as compared to Rs 96.16 crore for the same quarter in the previous year. Total income of the company increased by 21.08% at Rs 2460.07 crore for quarter under review as compared to Rs 2031.74 crore for the quarter ended March 31, 2017.

On consolidated basis, the company has reported a rise of 6.97% in its net profit after taxes, share of profit/ (loss) of associates and joint ventures and non- controlling interests at Rs 1308.96 crore for the quarter ended March 31, 2018 as compared to Rs 1223.71 crore for the corresponding quarter in the FY17. However, total consolidated income of the company decreased by 1.11% at Rs 7279.85 crore for quarter under review as compared to Rs 7361.46 crore for the same quarter ended previous year.

For the year ended March 31, 2018, the company has posted a net loss of Rs 494.59 crore as compared to net loss of Rs 22.84 crore for the previous year. However, total income of company increased by 9.24% at Rs 9075.64 crore for year under review as compared to Rs 8308.28 crore for the year ended March 31, 2017.

For the year ended March 31, 2018, on the consolidated basis, the company has posted a fall of 68.96% in its net profit after taxes, share of profit/ (loss) of associates and joint ventures and non- controlling interests at Rs 2161.55 crore as compared to Rs 6964.37 crore for the same period in the previous year. Total income of company decreased by 15.13% at Rs 27328.22 crore for year under review as compared to Rs 32201.59 crore for the year ended March 31, 2017.